12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Augment Bone Graft regulatory update

BioMimetic said it received a response letter from FDA for a PMA for the company's Augment Bone Graft requesting additional information from a pivotal trial. The agency also requested further information related to postapproval studies to monitor...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >